产品资料

Doxorubicin, Hydrochloride Salt **

如果您对该产品感兴趣的话,可以
产品名称: Doxorubicin, Hydrochloride Salt **
产品型号: LC D-4000
产品展商: 原装进口
产品文档: 无相关文档

简单介绍

Doxorubicin, Hydrochloride Salt **


Doxorubicin, Hydrochloride Salt **  的详细介绍
Doxorubicin, Hydrochloride Salt **

产品名称:Doxorubicin, Hydrochloride Salt
产品货号:LC  D-4000
产品规格:100 MG
Doxorubicin is an anthracycline antibiotic.  It is used in the treatment of a wide range of cancers.  Di Marco, A., et al.  "Adriamycin (NSC-123,127): a new antibiotic with antitumor activity."  Cancer Chemother. Rep. 53:  33-37 (1969).
Doxorubicin inhibited DNA and RNA but not protein synthesis in intact cells.  Momparler, R.L., et al.  "Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells."  Cancer Res. 36:  2891-2895 (1976).
Doxorubicin-conjugated HIV(P4/D10) antibody neutralized HIV-1IIIB and inhibited HIV replication in vitro.  It also protected mice from challenge with HIV-1IIIB/MuLV in vivo.  Johansson, S., et al.  "Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody."  AIDS 20:  1911-1915 (2006).
Combination with estradiol was found to enhance the apoptotic action of doxorubicin in estrogen-resistant MCF-7/LS cells but not in the estrogen-dependent MCF-7 breast cancer cells.  NF-κB may be a potential target for estradiol and doxorubicin in the therapy of the resistant breast cancer.  Scherbakov, A.M., et al.  "Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin."  Biosci. Rep.  Jul 27 (2010) [Epub ahead of print].
When patients were treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma, the risk of cardiotoxicity was significantly greater with doxorubicin-containing regimens and bolus administration than non-anthracycline regimens.  Smith, L.A., et al.  "Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials."  BMC Cancer 10:  337 (2010).
Doxorubicin hydrochloride is the active ingredient in the drug sold under the tradenames Adriamycin PFS, Adriamycin RDF, or Rubex®.  This drug has been approved in at least one country for use in patients with a wide range of cancers.  NOTE:  THE DOXORUBICIN, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT ADRIAMYCIN OR RUBEX®, AND IS NOT FOR HUMAN USE.
Our doxorubicin product is the hydrochloride salt, whose CAS number is given above.  The CAS number of the free base is 23214-92-8.
Other CAS numbers previously assigned to doxorubicin, namely 23257-17-2, 24385-08-8, 25311-50-6, and 29042-30-6, have been deleted by CAS and are no longer in use.
We note that one of our competitors, Medical Isotopes, as of October 31, 2011, is claiming 99.7% purity for its Doxorubicin, Hydrochloride Salt.  This claim is not credible in general chemical terms for this complex organic compound, nor in terms of the sensitivity and reproducibility of generally utilized analytical techniques.
Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 10 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A
WARNING:  Light-sensitive; minimize light exposure during handling.

产品留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!
使用指南 付款方式 客户关怀 **与保密 法律帮助 服务条款 监察中心信箱
分享到:

沪公网安备 31011002002623号